» Articles » PMID: 39377516

Group Sequential Testing of a Treatment Effect Using a Surrogate Marker

Overview
Journal Biometrics
Specialty Public Health
Date 2024 Oct 8
PMID 39377516
Authors
Affiliations
Soon will be listed here.
Abstract

The identification of surrogate markers is motivated by their potential to make decisions sooner about a treatment effect. However, few methods have been developed to actually use a surrogate marker to test for a treatment effect in a future study. Most existing methods consider combining surrogate marker and primary outcome information to test for a treatment effect, rely on fully parametric methods where strict parametric assumptions are made about the relationship between the surrogate and the outcome, and/or assume the surrogate marker is measured at only a single time point. Recent work has proposed a nonparametric test for a treatment effect using only surrogate marker information measured at a single time point by borrowing information learned from a prior study where both the surrogate and primary outcome were measured. In this paper, we utilize this nonparametric test and propose group sequential procedures that allow for early stopping of treatment effect testing in a setting where the surrogate marker is measured repeatedly over time. We derive the properties of the correlated surrogate-based nonparametric test statistics at multiple time points and compute stopping boundaries that allow for early stopping for a significant treatment effect, or for futility. We examine the performance of our proposed test using a simulation study and illustrate the method using data from two distinct AIDS clinical trials.

References
1.
Hammer S, Squires K, Hughes M, Grimes J, Demeter L, Currier J . A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337(11):725-33. DOI: 10.1056/NEJM199709113371101. View

2.
Saint-Hilary G, Barboux V, Pannaux M, Gasparini M, Robert V, Mastrantonio G . Predictive probability of success using surrogate endpoints. Stat Med. 2018; 38(10):1753-1774. DOI: 10.1002/sim.8060. View

3.
Wang S, Tsiatis A . Approximately optimal one-parameter boundaries for group sequential trials. Biometrics. 1987; 43(1):193-9. View

4.
Spiessens B, Lesaffre E, Verbeke G, Kim K, DeMets D . An overview of group sequential methods in longitudinal clinical trials. Stat Methods Med Res. 2001; 9(5):497-515. DOI: 10.1177/096228020000900506. View

5.
Kouw W, Loog M . A Review of Domain Adaptation without Target Labels. IEEE Trans Pattern Anal Mach Intell. 2019; 43(3):766-785. DOI: 10.1109/TPAMI.2019.2945942. View